Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 10/20 | 0.67 |
| ▸ | TGM1 | P22735 | 4/20 | 0.62 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7008818 | 0.92 | F13A1 (0.67) | F13A1TGM1CCR1MAPTGAA | |
| SCHEMBL7005641 | 0.90 | F13A1 (0.65) | F13A1TGM1CCR1TRPV4MEN1 | |
| SCHEMBL7010031 | 0.88 | F13A1 (0.78) | F13A1TGM1CCR1MEN1LMNA | |
| SCHEMBL7005912 | 0.86 | F13A1 (0.79) | F13A1TGM1CCR1 | |
| SCHEMBL7008746 | 0.86 | F13A1 (0.82) | F13A1TGM1MEN1KMT2AGAA | |
| SCHEMBL7003300 | 0.85 | F13A1 (0.74) | F13A1TGM1CCR1MEN1LMNA | |
| SCHEMBL7007822 | 0.84 | F13A1 (0.75) | F13A1TGM1CCR1MEN1LMNA | |
| SCHEMBL7007665 | 0.83 | F13A1 (0.71) | F13A1TGM1KMT2A | |
| SCHEMBL7008310 | 0.83 | F13A1 (0.76) | F13A1TGM1MEN1LMNAMAPT | |
| SCHEMBL7009658 | 0.82 | F13A1 (0.67) | F13A1TGM1MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225007-A1 | Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | APOTEX INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1348710-A1 | Sulfonamide derivatives of 3-substituted imidazo[1,2-D]-1,2,4-thiadiazoles and 3-substituted-[1,2,4]thiadiazolo[4,5-A]benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | Apotex Inc. (CA) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225007-A1 | Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | PIGS, FGB, SERPINE1 | F13A1 14/4885TGM1 7/4885CCR1 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.